Drugs / MP0274
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03084926 | Aug 2017 → Dec 2021 | neoplasm | Molecular Partners AG | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-10-12 | Molecular Partners AG | First patient dosed in phase 1 clinical study of Molecular Partners’ second proprietary oncology asset MP0274 molecularpartners.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MP0274 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03084926 ↗ |
| Modality | Other / unclassified | “MP0274, a DARPin® drug candidate” NCT03084926 ↗ |
| Route | Intravenous | “Intravenous infusion of MP0274” NCT03084926 ↗ |